We are grateful to the Cystinosis Research Team at the Robert Gordon University Aberdeen, and in particular researcher, Barbara Buchan, for allowing us to publish their research poster presentation. The poster was presented at the APS Conference in Nottingham.
CystagonTM, the primary medicine for treating Cystinosis, must be administered every 6 hours and the team are looking at alternative delivery mechanisms for Cysteamine (the key ingredient of Cystagon) to increase its effectiveness and reduce the frequency of administration. The Cystinosis Foundation UK has been providing financial support to the team to enable Barbara to undertake this research.
Their research includes looking at delivering Cysteamine as a dry powder to the lungs, in a manner not too dissimilar to inhalers used by asthmatics. It is believed the large surface area of the lungs will help achieve a more efficient delivery of Cysteamine throughout the body.
View Poster Presentation (requires Adobe Reader)